Levosimendan Accord (Levosimendan)

• Levosimendan is used in the management of heart failure syndromes where improved myocardial contractility and vasodilation are required.
• Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
• Chronic heart failure with reduced ejection fraction (adjunct): provides additional inotropic support when standard therapy is insufficient.
• Cardiogenic shock (adjunct): offers temporary haemodynamic stabilization in severe low‑output states.

• Levosimendan binds to cardiac troponin C, increasing the sensitivity of the contractile apparatus to calcium without raising intracellular calcium levels. It also opens ATP‑dependent potassium channels in vascular smooth muscle, producing vasodilation, and activates mitochondrial K(ATP) channels, contributing to cardioprotective effects.

Levosimendan may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient drop in blood pressure.
• Nausea: occasional gastrointestinal upset.
• Tachycardia: increased heart rate.
• Dizziness: related to blood pressure changes.

Serious or Rare Side Effects

• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Severe hypotension: may require vasopressor support.
• Myocardial ischemia: chest pain or ECG changes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Pulmonary edema: worsening respiratory status.

Levosimendan requires careful patient assessment and monitoring before and during infusion.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution in patients with liver dysfunction.
• Hypotension: observe blood pressure closely, especially when combined with other vasodilators.
• History of arrhythmias: continuous ECG monitoring is advised.
• Concomitant vasodilators: risk of additive blood pressure reduction.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, influencing its safety profile.

Major Interactions (Avoid)

• Sodium nitroprusside: additive hypotensive effect.
• Other calcium sensitizers: risk of excessive inotropy.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increased plasma concentrations.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt inotropic response.
• Diuretics: potential for volume depletion and hypotension.
• ACE inhibitors or ARBs: additive blood pressure lowering.
• Nitrates: enhanced vasodilation risk.
• Anticoagulants: monitor for bleeding if haemodynamic changes occur.